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1. Introduction 
Helicobacter pylori is now recognized as being a causative factor of gastroduodenal diseases 
such as chronic gastritis, gastric ulcer, duodenal ulcer, gastric cancer and gastric low-grade 
mucosa-associated lymphoma tissue (MALT). Long-term persistent inflammation, injury 
and reconstitution of gastric mucosa, and immunological reactions against the infected H. 
pylori are thought to be the causes of lesion formation. Various causative factors of H. pylori 
for inflammation and injury of gastric mucosa have been proposed. The most studied 
bacterial pathogenic factors are vacuolating toxin (VacA) produced by H. pylori, ammonium 
ion generated by H. pylori urease, and monochloramines formed from hypochlorite 
produced by phagocytic cells and the ammonium ion (Hofman et al., 2004; Xia & Talley, 
2001). These agents cause directly injury to the host gastric mucosa. Proinflammatory 
cytokines, such as interleukin (IL)-1, tumor necrosis factor-α (TNF-α), IL-6 and IL-8, are also 
induced by H. pylori. H. pylori activates the transcription factor NF-κB, which has a key role 
on inducing various inflammatory reaction including cytokine production, through type IV 
secretion system (Glocker et al., 1998). The type IV secretion system consisits of proteins 
encoded by genes located on cag pathogenicity island. 
In addition, lipopolysaccharide (LPS) is believed to contribute to the pathogenicity of this 
bacterium. LPS is a major component of Gram-negative bacterial outer membrane. It is 
known as an endotoxin and is a strong inducer of inflammatory reaction. H. pylori LPS, 
however, has much lower endotoxic activity than that of other typical Gram-negative 
bacteria, such as member of the Enterobacteriaceae family (Matsuyama et al., 2001; Muotiala 
et al., 1992; Nielsen et al., 1994; Perez-Perez et al., 1995; Semeraro et al., 1996). Strong 
endotoxin at infection sites, such as the systemic circulation system and digestive tract, 
should lead to sepsis, namely systemic inflammatory response syndrome (SIRS), and severe 
local inflammation, respectively.  The weak endotoxic activity is considered to be important 
for chronic infection. Weakly endotoxic LPSs are also reported for Chlamydia/Chlamydophila 
(Heine et al., 2003) and Porphyromonas gingivalis (Ogawa et al., 2000). These bacteria 
commonly infected humans chronically. 
Typical LPS acts as a pathogen-associated molecular pattern (PAMP). PAMPs are 
recognized by pattern recognition receptors (PRRs) of which the most studies are the Toll-
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like receptors (TLRs). Typical highly endotoxic LPS are recognized by the 
TLR4/MD2/CD14 complex, whereas the TLR that recognizes the weakly exdotoxic H. pylori 
LPS is controversial as discussed below. Bacterial flagella also act as a PAMP, and they are 
recognized by TLR5. Like the LPS, H. pylori flagella also show less activity as a TLR5 agonist 
(Andersen-Nissen et al., 2005). The PAMPs of H. pylori, therefore, share low potency as TLR 
agonists, namely they are weak inducers of inflammation. 
In addition to low endotoxic activity, H. pylori LPS has several unique features, for example 
structures that mimic host Lewis blood group antigens (Moran, 2008). In this review, the 
chemical characteristics, biological activities, and role in gastric carcinogenesis of H. pylori 
LPS will be described. In particular we will focus on our recent research into LPS as a 
pathogenic factor for carcinogenesis. 
2. General architecture of H. pylori LPS 
Like other typical bacterial LPS, H. pylori LPS consists of three region, namely lipid A, core 
oligosaccharide and O-polysaccharide (Fig. 1). The weakly endotoxic activity is due to the 
chemical structure of lipid A portion. In H. pylori LPS, the carbohydrate portion of lipid A 
consists of a glucosaminyl-β-1-6-glucosamine disaccharide backbone, as well as the typical 
lipid A. Whereas the lipid A of typical LPS derived from E. coli contains six fatty acid 
residues with relatively short carbon chain, such as C14 and C12, H. pylori lipid A contains 
three to five fatty acids with long carbon chain of C18 and C16 (Moran et al., 1997; Suda et 
al., 1997). Netea et al. (2002) describe that the molecular shapes, such as conical, cylindrical 
and intermediate, of lipid A are different between the highly endotoxic typical LPS and the 
weakly endotoxic LPS. The diversity of molecular shapes may cause the difference of 
endotoxic activity and usage of TLRs. Remodeling of lipid A structures occur in H. pylori by 
the action of phosphatase, ethanolamine phosphate transferase, 3-deoxy-D-manno-
octulosonic acid (KDO) hydrolase and deacylase (Tran et al., 2005). Hildebrandt & McGee 
(2009) report structural modifications of lipid A occur in an exogenous cholesterol-
dependent manner. Thus lipid A structures may vary among strains or change depending 
on culture conditions. 
 
 
Fig. 1. General architecture of H. pylori LPS 
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The core oligosaccharide region of H. pylori LPS has a characteristic structure among H. 
pylori strains, however, the detailed structure is distinct from the typical LPS (Aspinall et al., 
1997; Monteiro, 2001). It contains KDO and heptose residues similar to typical gram-
negative bacterial LPS. There is some heterogeneity among H. pylori strains. For example, 
heptose oligomer (heptan) or glucose oligomer (glucan) is found in some strains. 
One of the important features of H. pylori LPS is the O-polysaccharide region that bears the 
mimicking structures of the host carbohydrate antigens, Lewis antigens (Moran, 2008). It is 
interesting that Campylobacter species, which also belongs to spirillum, also shares host 
carbohydrate structures in gangliosides, such as GM1 and GQ1b (Yuki, 1999). Host Lewis 
antigens are recognized as a tumor antigen. Lex is also known as CD15, which is a marker 
for neutrophils. The existence of Lewis antigens, such as Lex, Ley, Lea and Leb, varies among 
H. pylori strains. Lewis antigns are considered to contribute to escape from a host immune 
response and to induction of an autoimmune response. The O-polysaccharide of most H. 
pylori strains consists of a lactosamine (galacotosyl-β1-4-N-acetyl-glucosamine) unit as the 
backbone chain. L-Fucose residues are partially substituted in the backbone chain and form 
a polymeric Lex structure. In addition, a high level of variability occurs in the non-reducing 
terminal end of the O-polysaccharide chain. For example, β1-3- or β1-4-linked galactose and 
α1-3- or α1-4-linked fucose can substitute on the N-acetyl-glucosamine residue, and α1-2-
linked fucose can occur on the galactose residue. The variable substitutions form various 
Lewis antigen structures (Fig. 2). 
 
 
 
 
 
 
Fig. 2. Structures of Lewis antigens 
Abbreviations. Fuc: L-fucose, Gal: D-galactose, GlcNAc: N-acetyl-D-glucosamine.  
3. Biological roles of Lewis antigens H. pylori LPS 
As described above, H. pylori Lewis antigens mimic host antigens and can thus modulate 
various host physiological responses, especially immunological reactions.  
The O-polysaccharide, in particular the polymeric Lex structure, has been shown to 
contribute to adhesion of H. pylori to human antral gastric mucosa. Galectin-3 is a gastric 
receptor for H. pylori Lex antigen (Fowler et al., 2006). Lewis antigens can interact with other 
host lectins. Interaction with two particular C-type lectins is important for the modulation of 
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immunological responses. One is Dendritic Cell Specific ICAM-3 Grabbing Non-integrin 
(DC-SIGN; CD209). Whereas Lewis antigen-negative H. pylori cells predominantly promotes 
a strong Th1 cell response, Lewis antigen-bearing cells interact with DC-SIGN on dendritic 
cells and induce IL-10, which promotes a Th2 response in a mouse infection model 
(Bergman et al., 2004). The other C-type lectin that interact with H. pylori LPS is surfactant 
protein D (SP-D) (Khamri et al., 2005; Murray et al., 2002). SP-D is involved in antibody-
independent clearance of bacteria. Levels of SP-D are increased in gastric mucosa with H. 
pylori-associated antral gastritis compared to normal gastric mucosa. The fucose residues of 
the O-polysaccharide chain are shown to be important for the recognition of SP-D. On the 
other hand, our recent study showed that D-galactose residue of H. pylori LPS is involved in 
interaction with SP-D as described below. 
Another important issue is formation of anti-Lewis antigen autoantibodies. Anti-Ley 
autoantibodies have been implicated in the pathogenesis of atrophic gastritis. The anti-Ley 
autoantiboides are found both in patients with atrophic gastritis and gastric cancer 
(Heneghan et al., 2001; Negrini et al., 1996). A candidate for the target of the autoantibodies 
is the β-chain of the H+,K+-ATPase, which is a proton pump (Appelmelk et al., 1996). Anti-
Lex autoantibodies are also found in H. pylori-infected patients (Heneghan et al., 2001; 
Negrini et al., 1996). Anti-Lex antibodies have been shown to activate neutrophils and 
enhance their adhesion to endothelium (Stockl et al., 1993) which could lead to 
inflammation and tissue damage. However, these antibodies induced by H. pylori do not 
react with synthetic Lewis antigens (Amano et al., 1997; Heneghan et al., 2001).  The actual 
specificity of the anti-Lewis antigen antibodies has not been clear yet. 
4. Antigenic epitopes of H. pylori LPS 
Whereas anti-Lewis antigen autoantibodies have been shown to be raised in response to H. 
pylori infection and to contribute to generation of diseases, we did not found significantly 
increased levels of any anti-Lewis antigen antibodies in H. pylori-infected gastroduodenal 
disease patients, H. pylori-positive individuals, and H. pylori-negative individuals (Amano et 
al., 1997). The reactivity of human antisera to H. pylori LPS derived from various strains was 
examined and a classification of H. pylori LPS has been proposed based on the antigenicity 
of O-polysaccharides to humans, namely highly-antigenic-epitope-carrying LPS and 
weakly-antigenic-epitope-carrying LPS (Yokota et al., 1998; Yokota et al., 2000b). The two 
epitopes were clearly characterized by examining serum absorption by LPS (Fig. 3). All H. 
pylori strains carrying the O-polysaccharide chain (namely, smooth strains) isolated in Japan 
have either one or the other epitope, but not both. The existence of these epitopes does not 
relate to that of the Lewis antigen structures. Most (over 95%) of H. pylori-infected 
individuals, including gastroduodenal patients and asymptomatic individuals, have a high 
titer of antibodies against the anti-highly-antigenic epitope in their sera. It is therefore 
proposed that the highly-antigenic epitope-carrying LPS are applicable to diagnosis of H. 
pylori infection (Amano et al., 1998) (Table 1). As an advantage, the LPS antigen is more 
stable against heat, drying and humidity than protein antigens. On the other hand, about 
half of H. pylori-infected individuals have antibodies against the weakly-antigenic epitope at 
a lower titer than those against the highly-antigenic epitope. The antibody titer against the 
weakly-antigenic epitope is significantly higher in gastroduodenal patients than in 
asymptomatic individuals with H. pylori infection (Yokota et al., 2000a). The antibodies 
against the weakly-antigenic epitope could relate to chronic and active infection of H. pylori.  
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Human serum containing: No. of sera 
  anti-highly antigenic epitope antibody only 31 (52.5%) 
  anti-weakly antigenic epitope antibody only 4 (6.8%) 
  both antibodies 24 (40.7%) 
Table 1. Frequency of anti-H. pylori LPS epitope antibodies in 59 sera derived from H. pylori-
infected individuals. 
 
 
 
 
Fig. 3. Reactivity of human serum containing antibodies against both highly-antigenic 
epitope and weakly-antigenic epitope in H. pylori LPS determined by Western blotting and 
absorption with LPS. 
Serum from one individual containing antibodies against both epitopes was absorbed with 
the indicated LPS at 37 C for 1 h, and used in Western blotting. LPS derived from strains 
GU2 and DU2 are highly-antigenic epitope-containing. LPS derived from strains CA2 and 
CA6 are weakly-antigenic epitope-containing. 
5. Usage of TLRs by H. pylori LPS 
TLR usage by H. pylori LPS remains controversial. An important issue to consider in these 
kinds of studies is the presence of contaminants with endotoxin-like activities, for example 
lipopeptides of H. pylori and other bacterial LPS, in the H. pylori LPS preparations. The 
extremely low level activity of H. pylori LPS means that very low level contamination cannot 
be ignored. Alternatively, as described above, structural heterogeneity exists in H. pylori 
lipid A and therefore different TLR usage could depend on lipid A structural variation. 
Whereas the weakly endotoxic activity of H. pylori LPS is widely accepted, TLR usage has 
been controversial with some researchers reporting that H. pylori LPS transduces signaling 
via the TLR4/MD2/CD14 complex like a typical LPS and others reporting signaling 
transduction via TLR2 as summarized in Table 2. Another report describes antagonistic 
activity of H. pylori LPS derived from some strains to TLR4-mediated typical LPS signaling 
(Lepper et al., 2005). 
Strains having the highly-antigenic epitope-carrying LPS are frequently found in those 
derived from patients with chronic gastritis. Strains having the weakly-antigenic epitope-
carrying LPS are predominantly found in those derived from patients with gastric cancer 
(Yokota et al., 2000b; Yokota et al., 1997) (Fig. 4).  
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Report Usage 
of TLR 
H. pylori 
strain 
Purification method 
of LPS 
Experimental evidences 
Kawahara 
et al,( 2001) 
TLR4 Various 
strains 
Hot phenol water/  
ultracentrifugation 
Using primary gastric mucosa cells 
derived from guinea pig. 
The cells are negative for TLR2. 
Ogawa et 
al. (2000), 
(2003) 
TLR4 206-1 Synthetic lipid A Using human peripheral blood 
mononuclear cells. 
The activities are neutralized by 
anti-TLR4 antibodies. 
Ishihara et 
al. (2004) 
TLR2 26695 Reextraction 
method described 
by (Hirschfeld et al., 
2000)
Luciferase reporter gene assay using 
HEK293 cells transfected with TLRs. 
Lepper et 
al. (2005) 
TLR2 Various 
strains 
Reextraction 
method described 
by (Hirschfeld et al., 
2000) 
Luciferase reporter gene assay using 
HEK293 and COS cells transfected 
with TLRs. 
LPS derived from some strains 
shares activity that antagonized 
TLR4.
Yokota et 
al. (2007) 
TLR2 Various 
clinical 
isolates 
Reextraction 
(treatment with 
proteinase K and 
lipoprotein lipases 
/ HICa) 
Luciferase reporter gene assay using 
HEK293 cells transfected with TLRs. 
Effect of the expression of dominant 
negative mutants of TLRs. 
Chochi et 
al. (2008) 
TLR4 A clinical 
isolate 
Not described 
(donated from 
Ohtsuka Co.) 
Using 4 gastric cancer cell lines. 
The activities are neutralized by 
anti-TLR4 antibodies. 
Smith et al. 
(2011) 
TLR2 3 reference 
strains and 
4 clinical 
strains 
Hot phenol 
water/proteinase K 
and nuclease 
treatment /  
ultracentrifugation
Using HEK293 cells transfected with 
TLR2. 
Using TLR2-negative gastric cell line 
AGS. 
 
 
 
 
 
 
Table 2. Interaction between H. pylori LPS and TLRs. 
aHIC: hydrophobic interaction chromatography. 
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Fig. 4. Antigenicity and antigenic type of H. pylori isolated from various clinical sources. 
Antigenicity index is expressed as the mean values of ELISA reading for 15 randomly 
selected serum samples from H. pylori-infected individuals.  Red open circle: Strains with 
LPS carrying the highly-antigenic epitope.  Blue close circle: Strains with LPS carrying the 
weakly-antigenic epitope.  Triangle: Rough strains. 
6. Novel biological activities of H. pylori LPS 
While a consensus has gotten on that H. pylori LPS share low toxicity as an endotoxin, some 
important biological activities have been observed. Chochi et al. (2008) reported that both H. 
pylori and E. coli LPS enhance the proliferation rate of gastric cancer cell lines. However, 
they also showed that H. pylori LPS, but not E. coli LPS, attenuates the cytotoxicity of 
mononuclear cells against gastric cancer cells, and downregulates perforin production in 
CD56+ natural killer cells cocultured with gastric cancer cells. Both the mitogenic activity, in 
common with E. coli, and the H. pylori-specific decrease in cytotoxicity of natural killer cells 
are likely to promote tumorigenesis. Grebowska et al. report that H. pylori LPS suppress 
phagocytic activity of human peripheral blood granulocytes (Grebowska et al., 2008) and H. 
pylori LPS-chased macrophages have low activity of lymphocyte proliferation (Grebowska et 
al., 2010).   They speculate that these activities contribute to chronic infection of H pylori. 
Slomiany et al. reported that H. pylori LPS disrupts gastric mucin synthesis, increases 
caspase-3 activity, causes apoptosis, and upregulates endothelin-1 and TNF-α via p38 and 
ERK MAP kinase cascade activation (Slomiany et al., 1999; Slomiany & Slomiany, 2002). 
Furthermore, it inhibits glycation and sulfation in gastric mucin biosynthesis (Slomiany et 
al., 1992). Kawahara et al. (2001) reported that the LPS of H. pylori, as well as that of E. coli, 
upregulates mitogen oxidase 1 (Mox1), which leads to the generation of superoxide anions.   
Young et al. (1992) report that it stimulates gastric mucosal pepsinogen secretion. These are 
likely to lead to injury of gastric mucosa. 
We found that pretreatment of gastric epithelial cell lines with H. pylori LPS enhanced the 
expression of TLR4 and also the responsiveness to E. coli LPS (Fig. 5-C) (Yokota et al., 2010). 
These gastric epithelial cell lines express markedly low levels of TLR4. H. pylori LPS  
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Fig. 5. A. Pretreatment with H. pylori LPS enhanced E. coli LPS-induced IL-8 production. 
Gastric cancer cell line MKN28 was treated with H. pylori LPS (100 ng/ml) for 24 h, then 
treated with E. coli LPS (1000 ng/ml) for 24 h, and IL-8 in the culture supernatants was 
measured by ELISA. LPS derived from GU2 and DU2 H. pylori strains is highly-antigenic 
epitope-carrying. LPS derived from CA2 and CA6 strains is weakly-antigenic LPS-carrying. 
LPS derived from CG10 strain is rough-type. 
B. TLR4 promoter activity with H. pylori CA2 LPS treatment determined by the luciferase 
reporter assay. Luciferase gene-conjugated promoters with a series of  mutations introduced 
in the transcription factor binding motifs indicated were used. NF-Y binding motif is 
indicated to be important for transcriptional induction of TLR4 by H. pylori LPS. 
C. Enhancement of TLR4 expression by H. pylori LPS and effect of inhibitors for MAP 
kinases. MKN28 cells were treated with H. pylori CA2 LPS (100 ng/ml) for 24 h, and then 
TLR4 on the cell surface was analyzed by flow cytometry. 
D. Enhancement of gastric epithelial cell growth by H. pylori LPS and effect of MAP kinase 
inhibitors. MKN28 cells were treated with H. pylori CA2 LPS (100 ng/ml) for 18 h, and then 
cell proliferation rate was measured by the uptake of 5-ethinyl-2’-deoxyuridine into DNA. 
MAP kinase inhibitors used were PD98059 (MEK1/2 inhibitor; 50 μM), FR180204 (ERK1/2 
inhibitor; 5 μM), SB202190 (p38 inhibitor; 5 μM), and SP600125 (JNK inhibitor; 10 μM). 
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Fig. 6. Proposed action of H. pylori LPS on gastric epithelial cells. 
H. pylori LPS upregulates TLR4 and augments cell proliferation via TLR2 and the MEK1/2-
ERK1/2 MAP kinase pathway in gastric epithelial cells. These activities are likely to enhance 
the inflammatory response, by increasing the activity of highly endotoxic typical LPS 
derived from other bacteria, and tumorigenesis. 
recognized by TLR2, preferentially as a TLR2/TLR1 complex, activated MEK-ERK MAP 
kinase cascade and the transcription factor NF-Y, and upregulated transcription of the TLR4 
gene (Fig. 5-B). In consistent with the in vitro observation, Asahi et al. (2007) indicate that 
higher expression of TLR4 is observed in biopsy specimens in the antral and corpus mucosa 
from H. pylori-infected patients than H. pylori-negative individuals. Backhed et al. (2003) 
report that primary gastric antral cells do not express TLR4, in contrast, several epithelial 
cell lines derived form gastric cancer do. The upregulated TLR4 in the gastric epithelial cells 
causes more efficient transduction of inflammatory signals by typical LPS, such as LPS 
derived from Enterobacteriaceae (Fig. 5-A).  
In concordance with the report of Chochi et al. (2008), H. pylori LPS was shown to 
upregulate the cell growth rate of gastric epithelial cell lines (Yokota et al., 2010) (Fig. 5-D). 
Activation of the MEK-ERK MAP kinase pathway via TLR2 activates NF-Y, and the NF-Y 
transcriptionally activates various cell cycle regulation genes, such as cyclin A1, cyclin B2, 
and E2F1. However, there are some contradictions between our report (Yokota et al., 2010) 
and the report of Chochi et al. (2008). We found that the mitogenic activity was H. pylori-
specific. With respect to TLR usage, Chochi et al. (2008) showed that anti-TLR4 antibody can 
neutralize the activity; however, we found that downregulation of TLR2 expression by 
siRNA diminished the activity (Yokota et al., 2010). 
The novel activities of H. pylori LPS reported by us (Yokota et al., 2010) (Fig. 6) are more 
potent in weakly-antigenic epitope-carrying LPS frequently isolated from gastric cancer, 
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than in highly-antigenic LPS-carrying strains. The weakly-antigenic LPS-carrying H. pylori 
strains are suggested to be more potent inducers of gastric cancer. The potent activities of 
the weakly-antigenic LPS may be due to interaction of H. pylori LPS  with host SP-D. A 
recent study indicates that SP-D enhances E. coli LPS-induced proinflammatory cytokine 
production upregulated by H. pylori LPS pretreatment (Yokota et al. unpublished results). 
SP-D interacts more strongly with weakly-antigenic epitope-carrying LPS than highly-
antigenic epitope-carrying LPS. The β-linked N-acetyl-glucosamine residue is suggested to 
be important for the highly-antigenic epitope, and digestion of the residue by a β-N-acetyl-
glucosamindase abolished the reactivity with anti-highly antigenic epitope antibody and 
appeared reactivity with anti-weakly antigenic epiotpe antibodies (Yokota et al., 
unpublished results). The β-galacotose residue is implicated in the weakly antigenic epitope 
and interaction with SP-D. 
7. Concluding remarks 
We propose the existence of two antigenic epitopes in H. pylori LPS. One of these, the 
weakly-antigenic epiotpe-carrying LPS, appears to occur frequently in strains derived from 
gastric cancer patients, as compared with chronic gastritis patients. The anti-weakly-
antigenic epitope antibody titers are higher in gastroduodenal patients than in 
asymptomatic H. pylori-infected individuals. The weakly-antigenic epitope-carrying LPS has 
stronger biological activity than the highly-antigenic epitope-carrying LPS. From these lines 
of evidence, strains carrying highly-antigenic epitope may change to strains carrying 
weakly-antigenic epitope during infection periods and disease progression status (Fig. 7). 
This phenotypic change leads to an escape strategy for H. pylori from host immune response  
 
 
 
Fig. 7. Relationship between changes of antigenic epitopes of H. pylori LPS, serum antibody 
titers to H. pylori LPS epitopes, and infection periods. 
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and to an increase in virulence. It is not clear whether the phenotypic change occurs by 
antigenic change of one strain or by microbial substitution. But the presence or not of a β-N-
acetyl-glucosamine residue of the polysaccharide chain of LPS appears to determine the 
antigenic conversion. Molecular studies of biosynthesis of LPS, for example 
glycosyltransferase expressions, are now required to elucidate these changes. 
We propose that H. pylori LPS enhances the inflammatory reaction induced by other 
bacterial LPS and upregulates the growth rate of epithelial cells via activation of the 
MEK1/2-ERK1/2 MAP kinase cascade. A putative role for H. pylori LPS as a pathogenic 
factor is shown in Fig. 8. In an H. pylori-uninfected gastric mucosa, Gram-negative bacteria 
invading orally do not cause a strong inflammatory response in gastric mucosa because the 
expression levels of TLR4 are low in gastric epithelial cells. On infection with H. pylori, H. 
pylori LPS upregulates TLR4 via TLR2 signaling in gastric epithelial cells. The upregulation 
of TLR4 leads to increased susceptibility of epithelial cells to typical LPS derived from other 
bacteria. Although the acids of gastric juice kill orally invading bacteria, LPS should be still 
stable. H. pylori LPS itself showed extremely weak endotoxic activity and therefore does not 
cause acute and systemic inflammatory reaction, such as sepsis. This strategy enables H. 
pylori to escape the host immune system and establish chronic infection. On the other hand, 
H. pylori LPS sets the stage for inflammatory response and tumorigenesis in the gastric 
mucosa during chronic infection, in other words, colonization. 
 
 
 
 
 
Fig. 8. Hypothesis for a pathogenic role of weakly-endotoxic H. pylori LPS in gastric mucosa. 
Uninfected state: Expression of TLR4 on the epithelial cells in gastric mucosa is low. So LPS 
derived from orally invaded bacteria does not induce a strong inflammatory response. 
H. pylori-infected state: H. pylori LPS itself causes low-level direct inflammation and tissue 
injury. At the same time, H. pylori LPS induces TLR4 expression on the epithelial cells in 
gastric mucosa, and therefore LPS with high endotoxic activity derived from orally invading 
bacteria causes higher level inflammation than in the H. pylori-uninfected state. 
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